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Abstract
Immune checkpoint inhibitors (ICIs) are emerging as the new standard of care for treating various metastatic cancers. It is 
known that effective anti-tumor immune responses are associated with a stronger presence of tumor-infiltrating lymphocytes 
(TILs) in solid tumor tissue. Cancer patients with relapsing–remitting multiple sclerosis (RRMS) are often under continu-
ous treatment with fingolimod, an immune-modulating drug that inhibits lymphocyte egress from secondary lymphatic 
organs. Little is known about the effect of fingolimod on ICI cancer therapy, as fingolimod may limit the number of TILs. 
Here we present three patients with RRMS, who developed various cancers during fingolimod treatment. Histology of all 
tumors consistently showed low numbers of TILs. A second biopsy taken from one of the tumors, a melanoma, revealed a 
significant increase of TILs after stopping fingolimod and starting pembrolizumab, indicating a surge in the number and re-
invigoration of T cells. Our study suggests that fingolimod limits the number of TILs in solid tumors and may, thus, inhibit 
anti-cancer immune responses.
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Introduction
Immune checkpoint inhibitors (ICIs) have ushered in a 
new era in the treatment of metastatic cancer. By target-
ing immune checkpoints, such as the programmed cell 
death protein 1 (PD1) or its ligand, ICIs lead to durable 
anti-cancer immune responses [1]. While they had been 
initially approved for therapy of metastatic melanoma and 
non-small cell lung cancer, they are now being used for 
treating various malignancies and have led to significant 
improvement of clinical outcomes and quality of life [2, 
3]. However, not all patients show therapy response and 
validated predictive biomarkers are scarce. One of the few 
reproducible markers is the proportion of tumor-infiltrat-
ing lymphocytes (TILs): a more pronounced pre-treatment 
lymphocytic infiltrate in solid tumors is associated with a 
better ICI therapy response [4]. Multiple sclerosis (MS) is 
a chronic inflammatory demyelinating disease of the cen-
tral nervous system (CNS) caused by auto-reactive T cells 
that migrate into the brain, where they induce inflamma-
tion and functional impairment. While the disease may be 
of multifactorial origin its exact mechanisms of the disease 
remain unknown [5]. For relapsing–remitting MS (RRMS) 
fingolimod has been established as a golden standard of 
care. Fingolimod is an active sphingosine 1-phosphate 
receptor (S1PR) antagonist that is orally administered. 
S1PRs are present on the surface of various cells including 
lymphocytes and neurons. Under normal circumstances 
activation of S1PRs overrides inhibitory signals from the 
homing C–C chemokine receptor 7, present mainly on 
naïve and central memory (CM) T cells, allowing these 
cells to egress from lymph nodes. However, in the pres-
ence of fingolimod, S1PRs are internalized and degraded, 
leading to the selective retention of naïve and CM T cells 
in secondary lymphoid organs and reducing the migration 
of lymphocytes to the CNS. In addition to its selective 
effects on the immune system, fingolimod is also thought 
to exert direct effects in the CNS, mainly by promoting 
oligodendrocyte-mediated remyelination and by reducing 
leakage of the blood–brain barrier [6].
The clinical introduction of fingolimod has marked 
an evolutionary step in the treatment of MS. However, 
its property to inhibit lymphocyte egress may negatively 
affect immune responses against cancer. Large pivotal 
phase III studies (FREEDOMS, FREEDOMS II, and 
TRANSFORMS) for Gilenya® (fingolimod) have shown 
no increased risk of developing neoplasms during therapy 
[7]. However, post-marketing surveillance studies and 
numerous case reports suggest that the risk for develop-
ing cancers during treatment may be underestimated, espe-
cially for melanoma and cutaneous lymphomas [8–11]. 
The use of fingolimod is particularly challenging in case of 
patients with newly diagnosed MS with a medical history 
of neoplasms. Here we present three patients, of whom one 
experienced a relapse of her melanoma and two developed 
new cancers during fingolimod treatment.
Methods
Clinical data and positron emission tomography/computed 
tomography scans were collected from three cancer patients 
with RRMS who were under fingolimod treatment dur-
ing first cancer diagnosis. All patients were treated in the 
Department of Oncology and Hematology of the Kanton-
sspital St. Gallen. Tumor samples that had been obtained 
for diagnostic histological examination were formalin-fixed 
and paraffin-embedded (FFPE) and stained with hematoxylin 
and eosin in the Institute of Pathology of the Kantonsspi-
tal St. Gallen using the standard protocols. Single epitope 
enzymatic immunohistochemistry on FFPE tissue was per-
formed on four-micron thick serial sections using a Leica 
BOND MAX automated immunostainer and the following 
antibodies: monoclonal mouse anti-human CD3 (Novocastra 
Biosystems, clone LN10, catalog number NCL-L-CD3-565, 
dilution 1:120, HIER—pH 9/30 min/100 °C, incubation for 
30 min), monoclonal mouse anti-human CD4 (Novocas-
tra Biosystems, clone 4B12, Catalog No. NCL-CD4-368, 
dilution 1:60, HIER—pH 9/30 min/100 °C, incubation for 
30 min), and monoclonal mouse anti-human CD8 (Dako/
Agilent, clone C8/144B, catalog number M7103, dilution 
1:120, HIER—pH 9/20 min/100 °C, incubation for 15 min). 
Micrographs were acquired with a Leica DM RA micro-
scope equipped with a Leica DFC420 C digital camera and 
processed using the Leica Application Suite version 3.8.0 
(Leica Microsystems, Switzerland), followed by assessment 
of TILs.
Results
Patient 1 A 61-year old woman was diagnosed with uveal 
melanoma in March 2012, which was treated with proton 
beam therapy, which lead to complete tumor remission. 
After several years of asymptomatic follow-up examinations 
in our oncological department she reported to have increas-
ing back pain that did not subside during periods of resting 
(Fig. 1a). A PET-CT scan in November 2016 showed meta-
static cancer with extensive spread to several bones, includ-
ing the spine. Tumor biopsy confirmed metastatic mela-
noma. The patient also suffered from RRMS and has been on 
treatment with fingolimod since 2013. Due to new metastatic 
disease fingolimod was stopped in January 2017. Despite 
the risk of MS flare-up during ICI treatment she received 
anti-PD1 treatment with pembrolizumab in January 2017, 
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which showed excellent response (Fig. 1b). After an initial 
response, she developed new bone metastases in July 2017 
and was switched to anti-CTLA4 treatment with ipilimumab. 
The first biopsy was obtained during fingolimod treatment 
and revealed very sparse lymphocytic infiltrate, as shown in 
Fig. 2a–d and in Fig. 3a, b. Interestingly, a follow-up biopsy 
taken after stopping fingolimod and during pembrolizumab 
treatment showed significantly more lymphocytic infiltration 
compared to the first biopsy (Fig. 3c, d), indicating immune 
system invigoration against the tumor. The patient showed 
good therapy response to ipilimumab and has not experi-
enced any MS flares during or after therapy.
Patient 2 A 51-year old women was admitted to the emer-
gency department due to dyspnea and chest pain in March 
2016. A thorax CT scan revealed pulmonary embolism and 
a tumor in the right lung. Histology of tumor tissue revealed 
adenocarcinoma of the lung. While the subsequent PET/CT 
scan showed no signs of distant metastases, it displayed 
increase contrast uptake at a lump in the left breast. Biopsy 
was performed and histology revealed intraductal breast can-
cer. The patient had been under treatment with fingolimod 
for RRMS since September 2015, which was stopped after 
tumor diagnosis. Similarly to patient 1, histology of both 
tumors showed a very sparse lymphocytic infiltrate in tumor 
tissue, as displayed in Fig. 2e–l.
Patient 3 A 51-year old woman was admitted to the gyne-
cology department due to a palpable lump in her left breast 
in June 2014 and histology confirmed intraductal breast 
cancer. She had been treated with fingolimod for RRMS 
since July 2012. Fingolimod was paused and the patient 
underwent complete resection of the tumor, sentinel lymph 
node biopsy and adjuvant chemo- and radiotherapy. After 
tumor clearance fingolimod was resumed. Also in her case, 
histology showed an almost total absence of lymphocytic 
infiltration (Fig. 2m–p).
Discussion
The management of patients with metastatic cancer and 
RRMS under fingolimod presents a special clinical chal-
lenge, as re-invigoration of T cells may induce flare-up of 
MS. In most phase III studies investigating ICI based treat-
ments patients with pre-existing autoimmune diseases have 
Fig. 1  Relapsing metastatic melanoma and response to anti-PD1 
treatment in a patient with fingolimod. a 18F-FDG PET/CT scan 
shows multiple bone metastases of melanoma, including the spine 
(centered by yellow crosshair). The patient has relapsing-remittent 
multiple sclerosis (RRMS) and is under treatment with fingolimod. R 
right, L left. b After ceasing fingolimod and starting treatment with 
pembrolizumab the follow-up PET/CT scan after 12 weeks shows a 
partial remission of all bone metastases including the spine. To date 
the patient showed no flares of RRMS, despite complete cessation of 
fingolimod
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typically been excluded. Indeed, there are reports of MS 
flares during ICI treatment [12]. A recent meta-analysis 
found that flares of MS during ICI treatment are rare, but 
severe [13]. To date, in our case, neither pembrolizumab 
nor ipilimumb lead to RRMS flares, despite cessation of 
treatment with fingolimod, while effectively treating can-
cer. In the case of metastatic cancer, such as in our patient, 
the argument for ICI therapy is evident as it outweighs the 
risk of autoimmune adverse events. For adjuvant ICI therapy 
however, a careful waging of potential risk and benefit is 
necessary to make the most appropriate choice on a case-
by-case basis.
Following the examination of tumor samples from 
cancer patients with MS, we found a potential associa-
tion between the use of fingolimod and reduced numbers 
of TILs, regardless of the type of cancer. This may be 
explained by the mechanism of fingolimod, which prevents 
lymphocyte egress from secondary lymphoid organs. Pre-
existing TILs in solid tumors have been shown to be an 
important biomarker in predicting response to ICI ther-
apy [4, 14]. Given that ICIs invigorate exhausted effector 
T cells [15], their presence in solid tumors indicates an 
effective anti-tumor response. Additionally, TILs have 
been shown to be crucial for better clinical outcome in 
cancer patients treated with other cancer drugs, such as 
chemotherapy [16]. Thus, the presence of TILs in solid 
tumors suggests effective anti-tumor activity, regardless 
of the given anti-cancer drug type. In our first patient, 
tumor histology during fingolimod treatment showed a 
remarkably less pronounced lymphocytic infiltrate com-
pared to tumor tissue taken after cessation of fingolimod. 
This potential TIL restriction of fingolimod is supported 
by a previous study, which found that fingolimod reduced 
the recirculation of  CD8+ effector T cells and their recruit-
ment to peripheral lesions in a mouse model of diabetes 
[17]. In another study the authors were able to demon-
strate that fingolimod inhibits anti-tumor immunity, lead-
ing to the development of myeloma and B-cell lymphoma 
[18]. On the other hand, cancer studies on mouse models 
suggest that fingolimod may have a sensitizing effect on 
certain cancer pathways and may increase the efficacy of 
chemo- or radiotherapy in some cancer types [19, 20]. 
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Fig. 2  Tumors of fingolimod-treated patients have low numbers of 
tumor-infiltrating lymphocytes. Representative micrographs of tumor 
samples stained with hematoxylin and eosin (left column) and single 
epitope immunohistochemistry for CD3 (center-left column) CD4 
(center-right column) and CD8 (right column). a–d Patient 1—mela-
noma. e–h Patient 2—lung cancer. i–l Patient 2—breast cancer. m–p 
Patient 3—breast cancer. Scale bars = 100 µm
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These data highlight the urgent necessity of additional 
studies to investigate the impact of fingolimod on anti-
tumor immune responses to assist physicians in making 
informed decisions for choosing the most appropriate MS 
therapy.
In summary, we present a patient with relapsing meta-
static melanoma and RRMS, who responded to ICI therapy 
and experienced no flare-up of RRMS despite stopping of 
fingolimod treatment. This argues for ICI safety during 
MS therapy. Furthermore, we found that fingolimod may 
be associated with lower TIL numbers in solid organs, 
suggesting a possibly impaired anti-tumor response during 
treatment. Additional large-scale studies and mechanistic 
explorations are necessary to substantiate these findings.
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Fig. 3  Increase in tumor-
infiltrating lymphocytes (TILs) 
in melanoma after cessation 
of fingolimod and initiation 
of pembrolizumab therapy. a, 
b Representative micrographs 
of metastatic melanoma 
biopsy from patient 1 during 
fingolimod therapy and before 
initiation of pembrolizumab: the 
tumor shows sparse lympho-
cytic infiltrate. a Hematoxylin 
and eosin (HE), b single epitope 
immunohistochemistry (IHC) 
for CD3. c, d Tumor biopsy 
from the same patient after ces-
sation of fingolimod and three 
cycles of pembrolizumab: both 
HE (c) and IHC for CD3 (d) 
show marked increase in TILs
 Cancer Immunology, Immunotherapy
1 3
need to obtain permission directly from the copyright holder. To view a 
copy of this licence, visit http://creat iveco mmons .org/licen ses/by/4.0/.
References
 1. Brahmer J, Reckamp KL, Baas P et al (2015) Nivolumab versus 
docetaxel in advanced squamous-cell non-small-cell lung cancer. 
N Engl J Med 373(2):123–135. https ://doi.org/10.1056/NEJMo 
a1504 627
 2. Wolchok JD, Chiarion-Sileni V, Gonzalez R et al (2017) Overall 
survival with combined nivolumab and ipilimumab in advanced 
melanoma. N Engl J Med 377(14):1345–1356. https ://doi.
org/10.1056/NEJMo a1709 684
 3. Omae K, Kataoka Y, Tsujimoto Y et al (2019) Publication statuses 
of clinical trials supporting FDA-approved immune checkpoint 
inhibitors: a meta-epidemiological investigation. BMC Cancer 
19(1):998. https ://doi.org/10.1186/s1288 5-019-6232-x
 4. Tumeh PC, Harview CL, Yearley JH et al (2014) PD-1 block-
ade induces responses by inhibiting adaptive immune resistance. 
Nature 515(7528):568–571. https ://doi.org/10.1038/natur e1395 4
 5. Dendrou CA, Fugger L, Friese MA (2015) Immunopathology of 
multiple sclerosis. Nat Rev Immunol 15(9):545–558. https ://doi.
org/10.1038/nri38 71
 6. Brinkmann V, Billich A, Baumruker T et al (2010) Fingolimod 
(FTY720): discovery and development of an oral drug to treat 
multiple sclerosis. Nat Rev Drug Discov 9(11):883–897. https ://
doi.org/10.1038/nrd32 48
 7. Khatri BO (2016) Fingolimod in the treatment of relapsing-remit-
ting multiple sclerosis: long-term experience and an update on the 
clinical evidence. Ther Adv Neurol Disord 9(2):130–147. https ://
doi.org/10.1177/17562 85616 62876 6
 8. Lebrun C, Rocher F (2018) Cancer risk in patients with mul-
tiple sclerosis: potential impact of disease-modifying drugs. 
CNS Drugs 32(10):939–949. https ://doi.org/10.1007/s4026 
3-018-0564-y
 9. Michiels Y, Bugnon O, Michiels JF et al (2019) Detection of a new 
melanoma in a patient treated with fingolimod. BMJ Case Rep. 
https ://doi.org/10.1136/bcr-2018-22795 1
 10. Velter C, Thomas M, Cavalcanti A et al (2019) Melanoma during 
fingolimod treatment for multiple sclerosis. Eur J Cancer 113:75–
77. https ://doi.org/10.1016/j.ejca.2019.03.011
 11. Stitt DW, Boes CJ, Flanagan EP et al (2018) A case of cutane-
ous large B cell lymphoma during treatment of multiple sclerosis 
with fingolimod. Mult Scler Relat Disord 19:115–117. https ://doi.
org/10.1016/j.msard .2017.11.014
 12. Yshii LM, Hohlfeld R, Liblau RS (2017) Inflammatory CNS dis-
ease caused by immune checkpoint inhibitors: status and perspec-
tives. Nat Rev Neurol 13(12):755–763. https ://doi.org/10.1038/
nrneu rol.2017.144
 13. Garcia CR, Jayswal R, Adams V et al (2019) Multiple sclero-
sis outcomes after cancer immunotherapy. Clin Transl Oncol 
21(10):1336–1342. https ://doi.org/10.1007/s1209 4-019-02060 -8
 14. Daud AI, Loo K, Pauli ML et al (2016) Tumor immune profiling 
predicts response to anti-PD-1 therapy in human melanoma. J Clin 
Invest 126(9):3447–3452. https ://doi.org/10.1172/JCI87 324
 15. Huang AC, Postow MA, Orlowski RJ et al (2017) T cell invigora-
tion to tumour burden ratio associated with anti-PD-1 response. 
Nature 545(7652):60–65. https ://doi.org/10.1038/natur e2207 9
 16. de Boo L, Cimino-Mathews A, Lubeck Y et al (2020) Tumour-
infiltrating lymphocytes (TILs) and BRCA-like status in stage III 
breast cancer patients randomised to adjuvant intensified plati-
num-based chemotherapy versus conventional chemotherapy. Eur 
J Cancer 127:240–250. https ://doi.org/10.1016/j.ejca.2019.12.003
 17. Pinschewer DD, Ochsenbein AF, Odermatt B et  al (2000) 
FTY720 immunosuppression impairs effector T cell peripheral 
homing without affecting induction, expansion, and memory. J 
Immunol 164(11):5761–5770. https ://doi.org/10.4049/jimmu 
nol.164.11.5761
 18. Lorvik KB, Bogen B, Corthay A (2012) Fingolimod blocks immu-
nosurveillance of myeloma and B cell lymphoma resulting in can-
cer development in mice. Blood 119(9):2176–2177. https ://doi.
org/10.1182/blood -2011-10-38889 2
 19. Gstalder C, Ader I, Cuvillier O (2016) FTY720 (Fingolimod) 
inhibits HIF1 and HIF2 signaling, promotes vascular remodeling, 
and chemosensitizes in renal cell carcinoma animal model. Mol 
Cancer Ther 15(10):2465–2474. https ://doi.org/10.1158/1535-
7163.MCT-16-0167
 20. Pchejetski D, Bohler T, Brizuela L et al (2010) FTY720 (fingoli-
mod) sensitizes prostate cancer cells to radiotherapy by inhibition 
of sphingosine kinase-1. Cancer Res 70(21):8651–8661. https ://
doi.org/10.1158/0008-5472.CAN-10-1388
Publisher’s Note Springer Nature remains neutral with regard to 
jurisdictional claims in published maps and institutional affiliations.
